Express News | Capricor Therapeutics Files Prospectus Relates to Resale by Selling Stockholder of up to 2.8 Mln Shares of Common Stock -SEC Filing

ReutersOct 22 17:13 ET

Insider Stock Research: New Fortress Energy, Marvell, and More

Quiver QuantitativeOct 21 16:58 ET

Capricor Therapeutics Analyst Ratings

BenzingaOct 21 12:03 ET · Ratings

Retail Investors Account for 45% of Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) Ownership, While Institutions Account for 14%

Simply Wall StOct 21 08:58 ET

Piper Sandler Initiates Capricor Therapeutics(CAPR.US) With Buy Rating, Announces Target Price $35

Moomoo NewsOct 21 05:31 ET · Ratings

Buy Rating for Capricor Therapeutics: Promising Deramiocel Development and Strategic Partnerships

TipRanksOct 21 05:15 ET · Ratings